












doi:10.101The Potential Utility of Bone Marrow or Umbilical Cord
Blood Transplantation For the Treatment of Type I
Diabetes Mellitus
Mohamed MabedThe pathology of type 1 diabetes mellitus (T1D) involves the autoimmune destruction or malfunction of
pancreatic b cells, leading to a lack of insulin. The absence of insulin is life-threatening, necessitating daily hor-
mone injections from an exogenous source. Insulin injections do not adequately mimic the precise regulation
of b cells on glucose homeostasis, however, eventually leading to complications in diabetic patients. There
currently is no definitive cure for T1D. Pancreas transplantation, although quite successful, is an invasive in-
tervention that is restricted to patients with advanced complications, requires constant immunosuppression,
and is severely limited by donor availability. Recent progress in human islet cell isolation and immunosuppres-
sive protocols has restored euglycemia in patients who received islet cells from 2 or 3 pancreas donors.
However, because of the scarcity of cadaver pancreata and the low yield of islet cells obtained by the pro-
cedure, not all patients have access to this surgical intervention. Thus, other therapeutic approaches are
needed to arrest immune aggression, preserve b cell mass, and provide efficient replacement. In this sense,
bone marrow and umbilical cord blood transplantation are promising possibilities that merit exploration. In
this review, we summarize multiple strategies that have been proposed and tested for potential therapeutic
benefit in patients with T1D.
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Type 1 diabetes (T1D) is an autoimmune disease
characterized by T cell-mediated destruction of
insulin-producing b cells [1,2]. The pathophysiology
of T1D in both humans and nonobese diabetic
(NOD) mice appears to be largely related to an
innate defect in the immune system, culminating in
a loss of self-tolerance and destruction of insulin-
producing b cells [3,4]. NOD mice, the prototypic
animal model for human T1D, have obvious defects
in central and peripheral tolerance [5] and exhibit var-
ious immune function abnormalities [6]. Both NOD
mice and humans with T1D have potential deficiencies
in at least two T cell populations intimately involved inDivision of Hematology/Medical Oncology, Oncology
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CD41CD251, or so called ‘‘regulatory,’’ T cells
(Tregs) [7-11]. In addition to defects in T cell-based
immune regulation, developmental and functional de-
fects have been reported in B lymphocytes as well as in
antigen-presenting cells (APCs) of both NOD mice
and humans with T1D, including defects of differenti-
ation and function of macrophages and dendritic cells
(DCs) [12-18]. The effector mechanisms responsible
for the destruction of b cells involve cytotoxic T cells as
well as soluble T cell products, including interferon
(IFN)-g, tumor necrosis factor (TNF)-a, and others
[19]. The course of autodestruction is subclinical until
the amount of b cell mass is insufficient to maintain
glucose homeostasis; thus, approximately 60%-80%
of the b cell mass has been destroyed by the time of
clinical diagnosis [20]. Currently, there is no definitive
cure for T1D. Insulin injection does not mimic the
precise regulation that b cells exert on glucose homeo-
stasis, ultimately leading to the development of
complications in patients with T1D [21].
Preservation of b cell mass has been attempted
with immunosuppressive agents. The rationale behind
immunosuppression is to stop immune aggression
toward the endocrine pancreas, facilitating its natural
reconstitution and maintain the residual functional
capacity of the b cell mass. Many clinical trials have455
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ing residual b cell loss. Short (#12 months) courses
of prednisone [22], azathioprine [23], azathioprine
plus prednisone [24], and cyclosporine [25] in random-
ized controlled trials have produced variable degrees of
improvement in C-peptide levels at the end of follow-
up compared with pretreatment values. These effects
did not persist after immunosuppressionwas discontin-
ued, however. The toxic effects of such drugs, concerns
about the risks associated with immunosuppression,
and the need for continuous treatment in an otherwise
healthy, young population have limited the routine use
of these therapies [26]. More recent studies using heat-
shock protein [27], antibodies against CD3 [28,29],
rabbit antilymphocyte globulin [30], and alum-
formulated glutamic acid decarboxylase [31] have
shown only transient increases followed by slower de-
clines of C-peptide levels during follow-up. Moreover,
almost all patients required the administration of
exogenous insulin.
Currently, the only viable approach to reversing
T1D involves whole pancreas or islet cell transplanta-
tion in association with nonspecific immunosuppressive
therapy [32]. Pancreas transplantation consistently
establishes an insulin-independent, normoglycemic
state. The downside is the nephrotoxic nature of cyclo-
sporine used for immunosuppression [33]. This effect
may be diminished by the use of tacrolimus and, more
recently, sirolimus [34,35]. Pancreas transplantation,
although quite successful, represents a rather invasive
intervention that is restricted to patients with advanced
complications, requires constant immunosuppressive
therapy, and is severely limited by donor availability.
Transplantation of islet cells isolated from cadaver
pancreata has become increasingly successful with
new protocols and immunosuppressive drugs [36,37].
Besides precluding the need for daily insulin injections,
this treatment generally decreases complications of
T1D [37]. However, the scarcity of cadaver pancreata
and the low yield of islet cells obtained by the procedure
limits patients’ access to this surgical intervention.
Other therapeutic approaches are needed to arrest
immune aggression, preserve b cell mass, and support
efficient replacement protocols. In this sense, bone
marrow (BM) and umbilical cord blood (UCB) trans-
plantation offer promising possibilities that merit ex-
ploration. In this review, we summarize the various
strategies that have been proposed and tested for
potential therapeutic benefit for T1D.AUTOLOGOUSHEMATOPOIETIC STEM CELL
TRANSPLANTATION
Since 1996, organ-threatening systemic lupus eryth-
ematosus and other autoimmune diseases have been
successfully treated with high-dose immunosuppressive
therapy followed by autologous nonmyeloablative(NMA) hematopoietic stem cell transplantation
(HSCT) [38,39]. In many cases, organ function is
salvaged and even improved after transplantation.
Similarly, a lymphoablative scheme that destroys most
of the patient’s autoreactive and nonautoreactive
lymphocyte clones, followed by recovery of the
immunologic system, has been performed with
acceptable toxicity in a small number of patients with
T1D [40]. In that study, 15 patients with new-onset
(within 6 weeks from diagnosis) T1D (mean age, 19.2
years) underwent autologous stem cell mobilization
with cyclophosphamide (2 g/m2) and daily granulocyte
colony-stimulating factor (10 mg/kg/day), followed by
leukapheresis and cryopreservation of stem cells. Fol-
lowing conditioning with rabbit antithymocyte globlu-
lin (4.5 mg/kg) and cyclophosphamide (200 mg/kg),
the previously mobilized cells were reinfused in-
travenously. Fourteen of the 15 subjects were able to
discontinue insulin injections for at least 1 month
posttreatment, with the majority (80%) being able to
remain off insulin for more than 6 months.
Treatment-related toxicity was low, with no mortality.
Limitations of the study included the short follow-up
time, as well as a lack of convincing C-peptide data to
confirma treatment effect rather than a prolonged hon-
eymoon period resulting from dietary and exercise
changes associatedwith close posttransplantationmed-
ical observation [41,42]. Updated results for the
extended group of 23 patients followed for 7-58
months posttreatment were presented by Couri et al.
[43]. Twenty of the 23 patients became insulin-free
(12 continuously and 8 transiently) for as long as 4
years, associated with good glucose control and accept-
able incidence of adverse effects [43]. The exact mech-
anism of action of autologous HSCT in autoimmune
disorders is not fully understood. It may shift the bal-
ance between destructive immunity and tolerance
through as-yet-undefined mechanisms, such as clonal
exhaustion, suppressor cells, immune indifference,
cytokine alterations, changes in T or B cell clonality,
or changes in immunodominant autoantigens [38].
Indeed, autologous NMA HSCT was able to induce
prolonged and significant increases in C-peptide levels
associatedwith the absence or reduction of daily insulin
doses in a small group of patients with newly diagnosed
T1D. However, randomized controlled trials and fur-
ther biological studies are needed to confirm the role
of this treatment in changing the natural history of
T1D.ALLOGENEIC HSCT
Allogeneic HSCT could eliminate the abnormal
immunocompetent cells responsible for the develop-
ment of T1D. It has been proposed that induction of
chimerism after allogeneic HSCT might eliminate
the mature autoreactive T cells in the host peripheral
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effect mediated by donor T cells in the graft, and also
eliminate the de novo developed autoreactive T cells
through negative selection mediated by donor APCs
in the host thymus [44,45]. It has been reported that
diabetes in BB rats can be adoptively transferred to
both young BB rats and diabetes-resistant rats when
concavalin A-activated spleen cells of BB rats with
overt diabetes were introduced into these rats [46].
In contrast, allogeneic HSCT from normal rats into
BB rats has been shown to prevent diabetes [47]. These
observations suggest that abnormal immunocompe-
tent cells are responsible for the development of
T1D and that allogeneic HSCT, which replaces these
abnormal stem cells with stem cells from normal BM,
has prophylactic and curative effects in BB rats. Alloge-
neic HSCT could be used to treat autoimmune insuli-
nitis and prevent overt diabetes in NOD mice, but
allogeneic HSCT alone could not cure established
diabetes. This is because the b cells of the islets are
already destroyed by the time the disease is established
[48].
In humans, it has been shown that in allogeneic
HSCT, T1D can be transmitted in BM transplants,
meaning that the disease may be transmitted through
stem cells. The first case of adoptive transfer of T1D
in a human was reported by Vialettes et al. [49]. How-
ever, patients with T1D who underwent HSCT to
treat leukemia or other blood-borne diseases demon-
strated no improvement in their diabetes after trans-
plantation [50,51]. The explanation for this finding is
that these patients already had diabetes for several
years and had only small amounts of b cell mass [52];
and the HSCs used in such transplantations are not
able to differentiate into a significant number of b cells
and induce remission in patients with long-standing
disease.COMBINED ALLOGENEIC HSCT PLUS
PANCREAS OR ISLET CELL
TRANSPLANTATION
The HSC chimerism achieved through allogeneic
HSCT can induce tolerance to pancreas or islet cell
transplants.Whole pancreas or islet cell transplantation
is the most physiological approach to treating T1D
[32,36]. Currently, this approach is limited by the
requirement for high-dose chronic nonspecific immu-
nosuppression to prevent graft rejection. But, despite
the use of such agents, chronic rejection remains the
primary cause of late graft loss. Pancreatic tissue grafts
combined with allogeneic HSCT have been used to
treat overt T1D in NOD mice [53]. Also, islet cells
were coinfused with allogeneic BM cells and mesenchy-
mal stem cells (MSCs) into streptozotocin (STZ)-
induced diabetic rats who had received a conditioning
regimen consisting of antilymphocyte serum and 5 Gyof total body irradiation. Although all of the recipients
initially rejected the islet cells, half of them developed
stablemixed chimerism and donor-specific immune tol-
erance, as demonstrated by the engraftment of donor
skin and second-set islet cell transplants and acute rejec-
tion of third-party skin [54]. One aim of concomitant
allogeneic HSCT is to induce immunologic tolerance
to the donor type major histocompatibity complex-
encoded determinants, allowing the host to accept sub-
sequent allogeneic pancreatic grafts or islet cells from
the BM donor. Donor-specific tolerance eliminates
the need for immunosuppression and prevents the
development of chronic rejection. In contrast to solid
organ transplantation, HSCT requires limited continu-
ous immunosuppression for up to 3-6 months, depend-
ing on the underlying pathology. Chimerism results in
an incompletely understood process associated with
clonal exhaustion or clonal depression that prevents
the recipient from reacting to the donor or vice versa
[55,56]. These findings suggest a potential use for
concomitant transplantation of allogeneic BM cells
with or without MSCs for induction of hematopoietic
chimerism and subsequent immune tolerance in
clinical pancreas or islet cell transplantation.
The widespread application of this therapeutic
approach is limited by the morbidity and mortality
associated with allogeneic HSCT, including graft-
versus-host-disease (GVHD), graft failure, and toxicity
of lethal conditioning regimens. Conditioning toxicity
can be overcome through the use ofNMA regimens. In
NMA transplantation, the immunosuppression load is
lower, resulting in a mixed chimerism that is sufficient
to prevent allogeneic reactions against the host. Such
nonmyeloablative transplant strategy with partial chi-
merism induction is one hope to induce tolerance in
the long run for solid organ transplants [57-60].
GVHD can be prevented by T cell depletion;
however, this is achieved at the cost of a substantial
increase in graft failure [61,62]. The dichotomy
between T cell depletion and graft failure has been
addressed by the recent discovery of CD81/TCR2
graft facilitating cells. The addition of small numbers
of these cells permits durable HSC engraftment
in allogeneic recipients and prevents GVHD [63].
The use of facilitating cells to promote HSC engraft-
ment after NMA conditioning may be a promising
approach to establishing tolerance in solid organ trans-
plantation [64].DIFFERENTIATION POTENTIAL OF BM STEM
CELLS INTO SURROGATE b CELLS
The recent remarkable progress in stem cell
biology has raised new hopes for the generation of sur-
rogate b cells from a number of nonpancreatic tissues
that can be induced to produce, process, and store in-
sulin; release it in response to physiological signals;
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67]. Tang et al. [68] demonstrated that a clonal popu-
lation of adult murine BM stem cells could be induced
to differentiate in vitro into insulin-producing cells
(IPCs) by culture in a high-glucose medium followed
by transfer to a low-glucose medium containing nico-
tinamide and exendin 4, two agents known to promote
b cell function. Even though these cells contained very
low levels of insulin, they were capable of correcting
hyperglycemia in vivo [68]. Oh et al. [69] reported
similar results using rat BM cultured under somewhat
different conditions.
BM transplantation results in differentiation of the
transplanted cells into various ectodermal, mesoder-
mal, and endodermal tissues in both mice and humans
[70,71]. Although some reports have challenged these
results by demonstrating that they were likely caused
by fusion of BM cells with differentiated cells rather
than representing a direct differentiation of BM cells
[72,73], other rigorous studies support the wide
differentiation potential of BM stem cells [74,75].
Studies in immunodeficient mice with chemically
induced pancreatic damage have shown a possible
capability of BM-derived stem cells to initiate b cell re-
generation. Improved b cell function after intensive
immunosuppression and autologous HSCT could be
explained by regeneration of b cells from BM stem
cells [76,77]. Insulin-positive cells, which appear in
a number of tissues in STZ-treated mice, have been
suggested to originate from BM [66]. The mechanisms
involved in pancreatic regeneration might be some-
what contrary to the classical concept of direct stem
cell differentiation into cells of the desired target tis-
sue, however. In their chemically induced diabetes
model, Hess et al. [75] determined that transplanted
BM-derived stem cells travel preferentially to damaged
organs and initiate tissue regeneration via the organ’s
own stem cell population. It is possible that adult
BM cells serve as a major source for continuous re-
newal of stem cells in other tissues, including the pan-
creas, and that in patients with T1D, the endogenous
BM provides cells for continuous islet cell renewal,
but newly formed b cells are rapidly destroyed by
autoimmunity.
Taken together, the findings of these studies sup-
port the potential of BM cells to differentiate into sur-
rogate b cells. However, further work is clearly needed
to determine to what extent BM-derived insulin pro-
ducing cells can mimic the function of mature b cells,
as judged by the ability to store large amounts of insulin
and release it in response to the array of physiological
signals that regulate insulin secretion from normal
b cells. On the other hand, the transplanted surrogate
b cells are likely to be exposed to recurring autoimmune
responses, as well as to allograft rejection. Thus, these
surrogate b cells need a mean of avoiding the immune
responses directed against b cells. A possible approachis HSCT combined with the coinfusion of IPCs
produced in tissue culture from the same BM graft.POTENTIAL UTILITYOF BM MSCS
MSCs are multipotent nonhematopoietic progen-
itor cells whose therapeutic potential is currently the
focus of many fields of research. MSCs are rare in
the BM, representing approximately 1 in 10,000 nucle-
ated cells. Although not immortal, MSCs have the
ability to expand many folds in culture while retaining
their growth and multilineage potential [78,79].
One possible application of MSCs is in the repair
of tissue injuries. Therefore, efficient delivery of
MSCs to the site of intended action is necessary. Sys-
temic delivery of MSCs has been reported by several
groups, with a significant contribution of the engrafted
MSCs to the regeneration of injured tissues. Chapel
et al. [80] investigated the potential of a combined in-
fusion of autologous ex vivo expanded hematopoietic
cells and MSCs for the treatment of multiorgan failure
syndrome following irradiation in a nonhuman pri-
mate model. Green fluorescent protein-expressing
MSCs were found in the injured muscle, skin, BM,
and gut of the treated animals up to 82 days postinfu-
sion. Infusion of human MSCs reduced the extent of
damage and accelerated the wound healing process in
NOD/scid mice who received 30 Gy of irradiation lo-
cally to the thigh, followed by i.v. injection of human
MSCs 24 hours after exposure [81]. In another study,
MSC green fluorescent protein-positive cells injected
i.v. homed to the kidney of C57/BL6 mice with
glycerol-induced acute renal failure, but not to the kid-
ney of normal mice [82]. Cho et al. [83] evaluated the
contribution of MSCs to the regenerative process after
liver injury and found that the transplanted MSCs mi-
grated directly to injured liver tissue without dispers-
ing to other organs. Furthermore, MSCs showed
differentiation potential into hepatocytes when cocul-
tured with injured liver cells [83]. Despite the fact that
MSCs can get trapped in the lungs, evidence has accu-
mulated to show that MSCs are capable of homing to
injured tissues after i.v delivery [84-86].
Similarly, MSC engraftment has been demon-
strated in several tissues after site-directed delivery,
particularly after injury. Several groups have used
BM cells to repair infarcted myocardium [87-89].
Hofstetter et al. [90] injected rat MSCs into the spinal
cords of rats rendered paraplegic 1 week after injury
and found that MSCs formed bundles bridging the
epicenter of the injury and guided regeneration
through the spinal cord lesion, thereby promoting re-
covery. Another group injected murine MSCs into the
lateral ventricle in the brains of 3-day-old mice and ex-
amined the brains 12 days later. MSCs had migrated
throughout the forebrain and cerebellum, suggesting
that MSCs mimic the behavior of neural progenitor
Biol Blood Marrow Transplant 17:455-464, 2011 459Potential of BM or CBT to Treat Type I Diabetes Mellituscells in this setting [91]. Intra-articularly injected
MSCs couldmobilize into the injured tissues and likely
contribute to tissue regeneration [92].
Although MSCs’ regenerative capability has been
a driving force behind initial studies examining their
therapeutic effectiveness, their immunomodulatory
properties are equally exciting in terms of exploring
their potential implications in various disease models,
including severe refractory autoimmune diseases [93].
The immunomodulatory properties of MSCs were
initially reported in T cell proliferation assays using
such stimuli as mitogens, CD3/CD28, and alloanti-
gens [94,95]. Different independent in vitro studies
performed with human and mouse cells have
confirmed that autologous or allogeneic BM-derived
MSCs strongly suppress T lymphocyte proliferation
triggered by cellular nonspecific mitogens or antigenic
peptides in a dose-dependent manner [95-98]. Studies
in animal models have shown that BM-derived MSCs
play a critical role in regulating the immune response
in in vivo settings as well. Autoimmune-prone mice
that underwent allogeneic HSCT with cotransplanta-
tion of donor bone as a stromal cell source survived for
48 weeks after transplantation without recurrence of
any autoimmune effects [99]. Among the early reports
responsible for stimulating interest in MSCs was
a study by Bartholomew et al. [94] in which the
investigators demonstrated that donor MSCs admin-
istered i.v. to major histocompatability complex-
mismatched recipient baboons before placement of
second- and third-party skin grafts resulted in pro-
longed allograft survival. Zappia et al. [100] studied
the immunoregulatory ability of murineMSCs to treat
myelin oligodendrocyte glycoprotein–induced experi-
mental autoimmune encephalomyelitis in C57BL/6J
mice. MSCs have been successfully used to treat
steroid-refractory GVHD in both experimental
animals [54] and humans [101,102].
MSCs have specific immunomodulatory proper-
ties that appear to be capable of disabling immune
dysregulation that leads to b cell destruction in T1D.
MSCs can regulate diabetes through a direct effect
by presenting differential levels of negative costimula-
tory molecules and secreting regulatory cytokines,
such as transforming growth factor-b and interleukin
(IL)-10 [103], that control Tregs and autoreactive
T cells. MSCs can correct the dysregulation observed
at the level of b cells [104,105] andNKT cells [106-108]
as well. Given the data demonstrating that interaction of
MSCs with DCs results in the formation of regulatory
DCs [109,110], Abdi et al. [111] proposed that MSCs
might regulate T1D indirectly by regulating DC func-
tion. MSCs also exert anti-inflammatory effects that
might be important to maintaining peripheral toler-
ance. The immunomodulatory functions of human
MSCs were examined by coculturing them with puri-
fied subpopulations of immune cells. The humanMSCs altered the cytokine secretion profile of DCs,
naive and effector T cells, and NKT cells to induce
a more anti-inflammatory or tolerant phenotype. Spe-
cifically, the human MSCs caused mature type 1 DCs
to decrease TNF-a secretion and mature type 2 DCs
to increase IL-10 secretion; caused T(H)1 cells to de-
crease secretion of IFN-g and T(H)2 cells to increase
secretion of IL-4; resulted in an increase in the propor-
tion of regulatory T cells; and decreased the secretion
of IFN-g from NKT cells [112].
Taken together, the foregoing findings suggest
that BM-derived MSCs can provide potential therapy
for T1D, although the mechanism remains controver-
sial. BM-MSC donors were sequentially cultured
under specially defined conditions, and the extent of
differentiation toward b cell phenotype was evaluated
systemically. After induction, the human BM-MSCs
formed spheroid islet-like clusters containing IPCs,
as confirmed by dithizone staining and electron mi-
croscopy. These IPCs expressedmultiple genes related
to the development or function of pancreatic b cells,
including NKX6.1, ISL-1, Beta2/Neurod, Glut2, Pax6,
nestin, PDX-1, ngn3, insulin and glucagon. The coex-
pression of insulin and c-peptide in IPCs was detected
by immunofluorescence. Moreover, the IPCs were
found tobeable to release insulin in aglucose-dependent
manner and ameliorate the diabetic condition of
STZ-treated nude mice [113]. Similarly, BM-derived
MSCs from diabetic patients can differentiate into
functional IPCs under certain conditions in vitro. Typ-
ical islet-like cell clusterswere observed; these differen-
tiated cells expressed nestin, PDX-1, Neurogenin3, Pax4,
insulin, glucagon. The cells were seen to secrete insulin
in response to different concentrations of glucose stim-
ulation. This suggests that a diabetic patient’s own
BM-derived MSCs can serve as a feasible source of au-
tologous IPCs for b cell replacement [114].
Dong et al. [115] investigated the status of BM-
MSCs in experimental diabetic rats and demonstrated
the rescue of experimental diabetes by diabetic MSC
transplantation. Allogeneic MSC transplantation re-
duced blood glucose levels in recipient rats. A rela-
tively small quantity of transplanted diabetic MSCs
survived and transdifferentiated into IPCs in the pan-
creas of recipient rats [115]. In another study, MSCs
from Wistar rat BM were induced to differentiate in
vitro to b cells. These cells demonstrated glucose-
dependent insulin secretion and when transplanted
into STZ-induced diabetic rats could down-regulate
blood glucose levels [116]. Lee et al. [117] reported
that infusion of human MSCs improved hypergly-
cemia and increased blood levels of mouse insulin in
STZ-induced diabetic NOD/scid mice. A few of the
human cells used in that study engrafted into the pan-
creas and differentiated so as to express both PDX-1
and human insulin. The major effect of this human
MSC treatment was to increase the number of mouse
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new islets appeared to bud off pancreatic ducts, which
are the source of islets during early pancreatic develop-
ment [118].
Although T1D can develop at any age, it occurs
mainly during childhood and adolescence, making the
safety of interventions a primary consideration. Alloge-
neic MSCs can be safely transplanted in children with
osteogenesis imperfecta without provoking an immune
response, and some cells have been found to home to
the BM [119,120]. MSCs can be expanded effectively
by culture, and cotransplantation of allogenic culture-
expanded MSCs and HSCs has been reported to be
feasible and safe [121]. For example, in breast cancer pa-
tients receiving autologous peripheral blood progenitor
cell (PBPC) infusion, MSC infusion at the time of the
PBPC transplantation produced rapid hematopoietic
recovery, suggesting thatMSCinfusionaftermyeloabla-
tive therapy might have a positive impact on hemato-
poiesis [122]. In an opened-label, multicenter trial,
coadministration of culture-expanded MSCs with
HLA-identical sibling-matched HSCs in patients with
a hematologic malignancy was well tolerated, with no
infusion-related adverse events [123].
To date, the role of MSCs in T1D remains unex-
plored. Future efforts in this area will provide insight
into the function of MSCs as immunomodulators of
the autoimmune response, as well as a source for
stem cells for tissue repair and provide a proof of prin-
ciple to translate to clinical trials in humans. Indeed, a
clinical trial is currently recruiting patients with T1D
diagnosed within 10 days of enrollment (Clinical
Trials.gov identifier: NCT01068951). The patients
will be treated with MSCs. The investigators’ main
hypothesis is that the development of autoimmune
diabetes might be halted at diagnosis by the MSCs’
immunomodulatory properties. Another study that is
currently recruiting participants is designed to evalu-
ate the safety and efficacy of cotransplantation of islet
cells and MSCs in patients with T1D (ClinicalTrials.
gov identifier: NCT00646724). The researchers hy-
pothesize that MSC infusion might benefit the islet
cell transplantation by protecting the islets from inflam-
matory damage, immunomodulation, and engraftment
promotion.UCB TRANSPLANTATION
The potential of UCB in future T1D interven-
tional therapies is immense. In an era where the mere
mention of stem cell therapies stirs controversy, the
use of UCB is attractive, because it avoids much of
the debate surrounding this delicate issue. Compared
with BM and peripherally mobilized stem cells, UCB
is preferable because of its immediate availability,
absence of risk to the donor and (if autologous) the
recipient, and low risk of GVHD [124].The fact that UCB contains a large population of
immature unprimed highly functional regulatory T
lymphocytes may be the most important reason for ex-
ploring the therapeutic applications of UCB in T1D.
The population of highly functional regulatory T cells
in UCBmay function to decrease the inflammatory cy-
tokine response and anergize the effector T cells that
play a key role in the cellular-mediated autoimmune
process [125].
The ability of UCB-derived stem cells to differen-
tiate into a variety of non-blood cell types, including
hepatocytes, neural cells, and endothelial cells, has
been documented [126]. UCB stem cells have been
successfully directed to differentiate into insulin and
C-peptide-producing cells in vitro [127]. HumanUCB
mononuclear cells express pancreas-related genes, in-
cluding nestin, neurogenin-3, and Pax4 at the RNA
level [128]. In addition, HSCs isolated from UCB
have a greater proliferative potential associated with
an extended lifespan and the potential to promote in
vivo b cell regeneration. In one study, human UCB-
derived T cell-depleted mononuclear cells were trans-
planted into newbornNOD/scid/b2m
null mice [129]. In
that model, IPCs were generated from human UCB in
vivo, as evidenced by the presence of human insulin at
the RNA level and human chromosome-containing
insulin-positive cells in situ. The generation of these
IPCs could be mediated through both another
fusion-dependent and independent mechanisms [129].
In mouse models of T1D, human UCB mononuclear
cells were able to reduce blood glucose levels and
increase survival [130].
Haller et al. [131] hypothesized that autologous
UCB transfusion in the setting of T1D might help
mitigate the autoimmune process through a number
of possible mechanisms: (1) UCB regulatory T cells
may facilitate direct or bystander suppression of effec-
tor T cells or allow for the restoration of tolerance
through their inhibitory effects on multiple cell types;
(2) UCB stem cells may migrate to the damaged pan-
creas, where they differentiate into insulin-producing
b cells; and/or (3) UCB stem cells may act as nurse cells
to foster the proliferation of new islets from remaining
viable tissue. These authors embarked on a pilot study
to document the safety and potential efficacy of autol-
ogous UCB infusion in children with T1D. Under
their protocol, 23 patients withT1Dwith stored autol-
ogous UCB underwent a single i.v. infusion of autolo-
gous cells. The data for the first 15 patients who
completed 1 year of postinfusion follow-up have
been reported. The median age at infusion was 5.25
years, and the median time to infusion after diagnosis
was 17.7 weeks. The most important observation of
the study so far is that autologous UCB infusion in
young children with T1D is feasible and safe. The
therapy’s potential efficacy remains less clear, how-
ever. The available data suggest that autologous UCB
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infusion. As such, the 2-year postinfusion data for the
entire 23-subject cohortwill be important tomore con-
clusively document the efficacy of autologous UCB
infusion in T1D [132]. Another clinical trial is cur-
rently recruiting children with T1D who have stored
UCB (ClinicalTrials.gov identifier: NCT00989547).
The investigators’ goal is to transfuse autologous
UCB into 23 childrenwithT1D in an attempt to regen-
erate pancreatic islet insulin-producing b cells and im-
prove blood glucose control. As secondary goals, the
investigators aim to track the migration of transfused
UCB stem cells and study the potential changes in
metabolism/immune function leading to islet regener-
ation.CONCLUSION
Stem cells from BM and UCB have great potential
in the treatment of T1D. The use of autologous cells
versus allogeneic cells remains an open question.
The relative efficiency of recurring autoimmunity after
autologous HSCT compared with allogeneic HSCT is
unknown. Whatever the stem cell source, high-dose
immunosuppressive regimens seem to facilitate en-
dogenous mechanisms of b cell regeneration in early-
onset disease. In patients with long-standing T1D,
inactivation of the autoimmune response alone is not
sufficient and should be combined with strategies for
b cell regeneration, given the large b cell mass de-
stroyed in these patients. The reality is that multiple
therapeutic avenues need to be explored, and that
several modalities likely will need to be combined to
achieve the dream of safely and permanently reversing
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